Management Participation in Key Investor Conferences
4D Molecular Therapeutics (NASDAQ: FDMT), a pioneering biotechnology firm specializing in durable and disease-targeted therapies, is set to engage in several upcoming investor conferences. The company aims to showcase its innovative solutions with significant potential to transform treatment frameworks and improve patient outcomes.
Cantor Global Healthcare Conference Details
As part of its investor outreach, 4DMT will be participating in the Cantor Global Healthcare Conference. This event is scheduled for September. It provides an excellent platform for the management team to engage in meaningful discussions about the company’s future.
Presentation Schedule
The details of the presentation are as follows:
- Presentation Date: September 4, 2025
- Presentation Time: 11:30 a.m. ET
Investors eager to follow the presentation can access the webcast.
H.C. Wainwright Annual Global Investment Conference
Another significant event on the calendar is the H.C. Wainwright 27th Annual Global Investment Conference. This allows for broader engagement from potential and current investors about what 4DMT is working on.
Key Details
The schedule for this conference includes:
- Presentation Date: September 9, 2025
- Presentation Time: 10:00 a.m. ET
Similar to the previous conference, the presentation will be available via webcast.
Morgan Stanley Annual Global Healthcare Conference
Furthermore, 4DMT will also attend the Morgan Stanley Annual Global Healthcare Conference, another cornerstone event for the company.
Event Highlights
Here are the details to note:
- Presentation Date: September 9, 2025
- Presentation Time: 1:50 p.m. ET
Viewers can tune in through the webcast.
Archived Webcast Access
For those unable to attend live, archived webcasts will be made available on the “Investors” section of the 4DMT website for up to one year post-event. This feature ensures all interested parties can stay informed about the company’s developments.
About 4D Molecular Therapeutics
4DMT is recognized for advancing therapies that are targeted towards specific diseases, with an emphasis on transforming treatment paradigms. Its leading product candidate, 4D-150, focuses on addressing blinding retinal vascular diseases through innovative delivery methods. This therapy significantly minimizes the treatment challenges typically associated with conventional bolus injections.
The current primary indication for 4D-150 is wet age-related macular degeneration, while it is also being developed for diabetic macular edema. Another groundbreaking product is 4D-710, which has demonstrated effective delivery of the CFTR transgene into the lungs for cystic fibrosis patients.
As of now, all of the company’s product candidates remain under clinical or preclinical development and have not yet received marketing approval from the U.S. Food and Drug Administration or any equivalent authorities. Therefore, representations about the safety and efficacy of these products for their intended therapeutic uses should be approached with caution.
Frequently Asked Questions
What upcoming conferences will 4D Molecular Therapeutics attend?
They will participate in the Cantor Global Healthcare Conference, H.C. Wainwright Annual Global Investment Conference, and Morgan Stanley Annual Global Healthcare Conference.
Who is the management team at 4DMT?
The management team includes leaders from various sectors of biotechnology, engaged in showcasing their innovative work in upcoming conferences.
What is 4DMT's lead product candidate?
The lead product candidate is 4D-150, aimed at treating wet age-related macular degeneration and diabetic macular edema.
Where can I find archived webcasts from these conferences?
Archived copies will be available for up to one year on the Investors section of the 4DMT website.
How can I contact 4D Molecular Therapeutics?
For media inquiries, you can reach Jenn Gordon at dna Communications. For investor relations, contact Julian Pei, Head of Investor Relations and Strategic Finance.
